Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk
Year: 2017
Type: review
Abstract: Obesity-related sub-acute chronic inflammation has been associated with incident type 2 diabetes and atherosclerotic cardiovascular disease. Inflammation is increasingly considered to be a pathologic mediator of these commonly co-occurring diseases. A growing number of preclinical and clinical studies support the inflammatory hypothesis, but clinical trials to confirm the therapeutic potential to target inflammation to treat or prevent cardiometabolic conditions are still ongoing. There are multiple inflammatory signaling pathways. Regulation is complex, with substantial crosstalk across these multiple pathways. The activity of select pathways may be differentially regulated in different tissues. Pharmacologic approaches to diabetes management may have direct or indirect antiinflammatory effects, the latter potentially attributable to an improved metabolic state. Conversely, some antiinflammatory approaches may affect glucose metabolism and cardiovascular health. To date, clinical trials suggest that targeting one portion of the inflammatory cascade may differentially affect dysglycemia and atherothrombosis. Understanding the underlying biological processes may contribute to the development of safe and effective therapies, although a single approach may not be sufficient for optimal management of both metabolic and athrothrombotic disease states.
DOI: 10.1172/jci88884
Authors: Allison B. Goldfine, Steven E. Shoelson
Institutions: Joslin Diabetes Center, Harvard University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: Mechanism-Based Biomarkers for Glucose-Lowering in TINSAL-T2D, Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate, Cardiovascular Inflammation Reduction Trial (CIRT), Intrinsic anti-inflammatory actions of AMPK activation rendered through a novel immunometabolic AMPK-mTOR-NFkB Pathway, Targeting Neutrophils and Leukotrienes to Treat Type 2 Diabetes, EFFECTS OF IKKB and NFkB IN INSULIN RESISTANCE, IKK MEDIATED INSULIN RESISTANCE AND IN VIVO REVERSAL, G2833296188, Mediators and Modifiers of NF-kappaB in Insulin Resistance, TOLL RECEPTOR ACTIVATION OF NF-kB IN INSULIN RESISTANCE AND T2DM, Metabolic Syndrome, Inflammation and Vascular Remodeling, Xanthine oxidase inhibition raises intracellular purines to activate AMPK, improve glucose control and decrease fatty liver and atherosclerosis in type 2 diabetes, Diabetes Research Center
OpenAlex ID: W2560939303
